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F-fluorodeoxyglucose positron emission tomography (FDG-PET) for predicting the pathological complete response (pCR) of primary breast cancer in the neoadjuvant chemotherapy setting [1] . In this article, we present a close association between pathological response and the maximum tumor standardized uptake value (SUVmax) measured by FDG-PET scan prior to chemotherapy. Estrogen receptor (ER)-positive breast cancer (as determined by immunohistochemistry) presented a significantly lower baseline SUVmax (n= 70; mean± SD, 6.51± 3.51) than HER2 and triple-negative ones (n= 24; mean± SD, 8.58± 4.1; p = 0.02 and n = 17; mean ± SD, 9.37 ± 5.78; p = 0.01, respectively). The baseline SUVmax of ER-positive tumors in which pCR was achieved (n= 7; mean± SD, 9.8± 4.0) was significantly higher than that in tumors in which no pCR was achieved (n = 63; mean ± SD, 6.4 ± 3.1; p = 0.006). Therefore, we hypothesized glucose hypermetabolism in luminal B tumors may result in chemotherapy responsiveness.
Using a single-gene expression assay, TargetPrint ® (Agendia, Amsterdam, The Netherlands) and a 70-gene expression classifier, MammaPrint ® (Agendia) [2, 3] , we divided 20 patients with ER-positive primary breast cancer into luminal A and luminal B subtypes and compared the tumor SUVmax value between the two groups. The demographics of these groups are shown in Table 1 .
A significantly higher SUVmax was measured for luminal B tumors (n = 10; mean ± SD, 7.6 ± 5.6) than for luminal A tumors (n= 10; mean± SD, 2.6± 1.2; p= 0.01) (Figure 1 ). At the threshold of 5.0, the sensitivity and specificity of FDG-PET to identify tumors of the luminal B subtype were 60% and 100%, respectively. The area under the curve (AUC) analysis showed that SUVmax was an acceptable discriminator (AUC = 0.878; 95% confidence interval [CI], 0.647-0.981) with results comparable with those of the Ki-67 labeling index (LI) (AUC, 0.878; 95% CI, 0.647-0.981), a proliferative marker used to discriminate luminal B tumors in clinical practice ( Figure 2 ). When SUVmax and Ki-67 LI were combined, the diagnostic performance improved (AUC= 0.933; 95% CI, 0.72-0.997).
Jin et al. [4] reported that among 273 breast cancer patients who received neoadjuvant chemotherapy, higher baseline
Genomic Profiling Shows Increased Glucose Metabolism in Luminal B Breast Cancer
We had previously reported a close association between pathological response and the maximum tumor standardized uptake value (SUVmax) measured by 18 F-fluorodeoxyglucose positron emission tomography prior to chemotherapy in estrogen receptor (ER)-positive breast cancer. We hypothesized that glucose hypermetabolism by luminal B tumors may result in chemotherapy responsiveness. Using a single-gene expression assay, TargetPrint ® (Agendia) and a 70-gene expression classifier, MammaPrint ® (Agendia), we divided 20 patients with ERpositive primary breast cancer into luminal A and luminal B subtypes and compared the tumor SUVmax value between the two groups. A significantly higher SUVmax was measured for luminal B tumors (n= 10; mean± SD, 7.6± 5.6) than for luminal A tumors (n= 10; mean± SD, 2.6± 1.2; p= 0.01). Glucose hypermetabolism could help predict intrinsic subtyping and chemotherapy responsiveness as a supplement to ER, progesterone receptor, HER2, and Ki-67 histochemical scores.
SUVmax of the tumor and ER negativity were independent indicators of pCR. Despite the low number of ER-positive breast cancer patients who achieved pCR in that study, higher SUVmax in pCR than in non-pCR was in agreement with the results of our study. The role of glucose metabolism in ERpositive breast cancer was examined by Osborne et al. [5] from the Memorial Sloan-Kettering Cancer Center, who identified 43.7% of FDG SUV-correlated genes as ER signal-related genes by cDNA microarray analysis.
The present study has some limitations: the sample size was too small, including patients with relatively small tumors, which may have been a cofounding factor that affected the SUVmax. Standardization is required for the use of quantitative FDG-PET as an imaging biomarker.
Currently, FDG-PET scanning is used for noninvasive detection of metastasis. In combination with one-stop examination, which evaluates the clinical staging of primary breast cancer, FDG-PET may provide invaluable information on intrinsic subtyping and chemotherapy responsiveness in addition to that obtained from ER, progesterone receptor, HER2, and Ki-67 histochemical scores. 
